ATAP Advocates
With Support from ATAP, States Continue to Make Headway in Enacting PBM Legislation
ATAP is pleased to report that five states have now passed legislation this year aimed at regulating PBMs in yet another sign that our coalition’s core message and extensive advocacy outreach is continuing to resonate not only with state lawmakers, but also with the general public.
ATAP Advocates
ATAP Praises Florida Governor For Signing PBM Bill into Law
ATAP thanks Florida Governor Rick Scott for signing the Prescription Drug Pricing Transparency legislation into law on Friday. The law will allow pharmacists to share whether the retail price of a drug is less than the amount a consumer would pay under their insurance, preventing Florida consumers from being overcharged when they purchase many prescription medicines.
ATAP Advocates
ATAP Sends Florida Governor Letter Supporting PBM Transparency Bill
On behalf of the Alliance for Transparent and Affordable Prescriptions (ATAP), I am writing to express our support for HB 351, a bill that seeks to increase transparency and regulation of pharmacy benefit managers (PBMs), and urge you to sign it into law.
The Columbus Dispatch
Bill targeting pharmacy benefit managers gets first hearing in Ohio House
A House committee opened hearings Tuesday on a bipartisan bill designed to lower the cost of prescription drugs.House Bill 479 — sponsored by Reps. Scott Lipps, R-Franklin, and Thomas E. West, D-Canton — takes aim at pharmacy benefit managers, known as PBMs, and other third-party administrators that operate as a middleman between insurance and drug companies.
ATAP Advocates
ATAP Applauds Florida Legislature for Passing PBM Bill
ATAP is pleased to report that a Florida bill aimed at regulating PBMs has passed unanimously through the House and Senate and now heads to Governor Rick Scott.
ATAP Advocates
New York Becomes Newest State to Pass PBM Legislation
ATAP is pleased to announce that New York has become the newest state to pass PBM reform legislation. Sponsored by Assemblymember Linda Rosenthal, A8781 was passed unanimously by both the New York House and Assembly and is waiting to be signed into law by Governor Andrew Cuomo.
ATAP Advocates
ATAP Responds to UnitedHealthcare Statement on Direct-to-Consumer Rebates, FDA Commissioner Scott Gottlieb Statement on Biosimilar Competition
The Alliance for Transparent & Affordable Prescriptions (ATAP) is encouraged by UnitedHealthcare’s announcement that it will start passing on savings from drug manufacturers directly to patients by applying manufacturer rebates and discounts to their medication costs at the point of sale.